Skip to content
HowShorted

Keros Therapeutics, Inc. short interest in 2021

In 2021, Keros Therapeutics, Inc.'s disclosed short interest ran from 3.13% of shares outstanding on 15 Jan 2021 to 3.49% on 31 Dec 2021, a change of +0.36 percentage points. The year's high was 4.65% on 14 May 2021 and its low 3.06% on 29 Jan 2021, averaging 3.89% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 12.83 days on 28 May 2021. Full history: Keros Therapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Keros Therapeutics, Inc. in 2021

2021 in figures

Start of year
3.13% (15 Jan 2021)
End of year
3.49% (31 Dec 2021)
Change
+0.36 pp
High
4.65% (14 May 2021)
Low
3.06% (29 Jan 2021)
Average
3.89%
Highest days to cover
12.83 (28 May 2021)
SEC filings marked
8

Every report in 2021

Keros Therapeutics, Inc. short interest in 2021
SettlementShort interestDays to coverFilings since previous
15 Jan 20213.13%5.02
29 Jan 20213.06%5.34
12 Feb 20213.42%6.87
26 Feb 20213.41%7.78
15 Mar 20213.48%7.81
31 Mar 20214.45%8.0110-K filed, results (8-K)
15 Apr 20214.47%6.09
30 Apr 20214.24%12.79
14 May 20214.65%6.2810-Q filed, results (8-K)
28 May 20214.29%12.83
15 Jun 20213.60%8.92
30 Jun 20213.76%3.84
15 Jul 20214.00%8.62
30 Jul 20214.22%10.42
13 Aug 20214.27%12.1710-Q filed, results (8-K)
31 Aug 20213.82%12.06
15 Sep 20213.66%6.43
30 Sep 20214.43%2.19
15 Oct 20214.29%8.40
29 Oct 20214.32%11.31
15 Nov 20213.37%3.9210-Q filed, results (8-K)
30 Nov 20213.48%6.23
15 Dec 20213.96%4.19
31 Dec 20213.49%4.61

See also: Keros Therapeutics, Inc.'s full history · most shorted US stocks of 2021 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.